US20040082798A1 - Novel amino dicarboxylic acid derivatives with pharmaceutical properties - Google Patents
Novel amino dicarboxylic acid derivatives with pharmaceutical properties Download PDFInfo
- Publication number
- US20040082798A1 US20040082798A1 US10/469,817 US46981703A US2004082798A1 US 20040082798 A1 US20040082798 A1 US 20040082798A1 US 46981703 A US46981703 A US 46981703A US 2004082798 A1 US2004082798 A1 US 2004082798A1
- Authority
- US
- United States
- Prior art keywords
- carbon atoms
- chain
- straight
- branched
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 amino dicarboxylic acid derivatives Chemical class 0.000 title claims description 179
- 150000001875 compounds Chemical class 0.000 claims abstract description 134
- 239000003814 drug Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 475
- 125000000217 alkyl group Chemical group 0.000 claims description 182
- 239000001257 hydrogen Substances 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 127
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 91
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 84
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 125000003545 alkoxy group Chemical group 0.000 claims description 78
- 229910052736 halogen Inorganic materials 0.000 claims description 66
- 150000002367 halogens Chemical group 0.000 claims description 66
- 229910052717 sulfur Inorganic materials 0.000 claims description 66
- 125000001188 haloalkyl group Chemical group 0.000 claims description 63
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 54
- 229910052757 nitrogen Inorganic materials 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 53
- 150000003254 radicals Chemical class 0.000 claims description 51
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 49
- 230000008569 process Effects 0.000 claims description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 45
- 125000005842 heteroatom Chemical group 0.000 claims description 43
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
- 229910052731 fluorine Inorganic materials 0.000 claims description 40
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 125000003342 alkenyl group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 229910052801 chlorine Inorganic materials 0.000 claims description 31
- 150000005840 aryl radicals Chemical class 0.000 claims description 25
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 25
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 21
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 21
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 20
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 229910052794 bromium Inorganic materials 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 229910052740 iodine Inorganic materials 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 229910052721 tungsten Inorganic materials 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 12
- 229910052720 vanadium Inorganic materials 0.000 claims description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims description 11
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 10
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 239000011737 fluorine Chemical group 0.000 claims description 10
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 9
- 125000004001 thioalkyl group Chemical group 0.000 claims description 9
- 150000007513 acids Chemical class 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 8
- 229910052727 yttrium Inorganic materials 0.000 claims description 8
- 229910052770 Uranium Inorganic materials 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 4
- 241001484259 Lacuna Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 150000002941 palladium compounds Chemical class 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000000565 sulfonamide group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 2
- 230000009424 thromboembolic effect Effects 0.000 claims description 2
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 58
- 208000037997 venous disease Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 111
- 239000000243 solution Substances 0.000 description 48
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 46
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 40
- 239000000203 mixture Substances 0.000 description 38
- 0 C.CC.C[V]C[Y].[2*]*[U]N(CC)[W]C Chemical compound C.CC.C[V]C[Y].[2*]*[U]N(CC)[W]C 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 29
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 26
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 25
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 150000003278 haem Chemical group 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000010992 reflux Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical class [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 12
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 229930195733 hydrocarbon Natural products 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000004936 stimulating effect Effects 0.000 description 10
- 239000004215 Carbon black (E152) Substances 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- PRHWSYDCSPJIKS-UHFFFAOYSA-N C1=CC2=C(C=C1)SC=C2.C1=CC=C2NC=CC2=C1.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=CNN=C1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNC1.C1CCNCC1.C1CNCCN1.C1COCCN1 Chemical compound C1=CC2=C(C=C1)SC=C2.C1=CC=C2NC=CC2=C1.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=CNN=C1.C1=COC=C1.C1=COC=N1.C1=CON=C1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNC1.C1CCNCC1.C1CNCCN1.C1COCCN1 PRHWSYDCSPJIKS-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 description 5
- 150000001728 carbonyl compounds Chemical class 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CRBLICRGRDSRAK-UHFFFAOYSA-N C1=CC2=C(C=C1)OC=N2.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNCC1.C1CNCCN1.C1COCCN1 Chemical compound C1=CC2=C(C=C1)OC=N2.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNCC1.C1CNCCN1.C1COCCN1 CRBLICRGRDSRAK-UHFFFAOYSA-N 0.000 description 4
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 4
- 102000014469 Guanylate cyclase Human genes 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- BSCPZUDZXWJATQ-UHFFFAOYSA-N [3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]methanol Chemical compound OCC1=CC=2CCCCC=2C=C1OCC1=CC=C(Br)C=C1 BSCPZUDZXWJATQ-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- LMYGCLJMZNGQNC-UHFFFAOYSA-N methyl 4-[[(5-ethoxy-5-oxopentyl)-[2-[6-methyl-3-[[4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]pyridin-2-yl]ethyl]amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OCC)CCC1=NC(C)=CC=C1OCC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 LMYGCLJMZNGQNC-UHFFFAOYSA-N 0.000 description 4
- LQWPYHCVMXMMNE-UHFFFAOYSA-N methyl 4-[[2-[3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethyl-(5-methoxy-5-oxopentyl)amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OC)CCC1=CC=2CCCCC=2C=C1OCC1=CC=C(Br)C=C1 LQWPYHCVMXMMNE-UHFFFAOYSA-N 0.000 description 4
- 125000002560 nitrile group Chemical group 0.000 description 4
- 229920005990 polystyrene resin Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229950003776 protoporphyrin Drugs 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- SFHRXXZCFAYSRK-UHFFFAOYSA-N 2-(bromomethyl)-3-[(4-bromophenyl)methoxy]-6-methylpyridine Chemical compound BrCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 SFHRXXZCFAYSRK-UHFFFAOYSA-N 0.000 description 3
- UONSDUXTIAFYDD-UHFFFAOYSA-N 2-[3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]acetonitrile Chemical compound C1=CC(Br)=CC=C1COC(C(=C1)CC#N)=CC2=C1CCCC2 UONSDUXTIAFYDD-UHFFFAOYSA-N 0.000 description 3
- BENKDPHBHMSIFD-UHFFFAOYSA-N 2-[3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethanamine Chemical compound NCCC1=CC=2CCCCC=2C=C1OCC1=CC=C(Br)C=C1 BENKDPHBHMSIFD-UHFFFAOYSA-N 0.000 description 3
- CZHVRRLGLCGBCY-UHFFFAOYSA-N 2-[3-[(4-bromophenyl)methoxy]-6-methylpyridin-2-yl]acetonitrile Chemical compound N#CCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 CZHVRRLGLCGBCY-UHFFFAOYSA-N 0.000 description 3
- FAGFOUTVIWDNMV-UHFFFAOYSA-N 2-[3-[(4-bromophenyl)methoxy]-6-methylpyridin-2-yl]ethanamine Chemical compound NCCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 FAGFOUTVIWDNMV-UHFFFAOYSA-N 0.000 description 3
- FOIDGFDGJSUMLK-UHFFFAOYSA-N 2-[4-(chloromethyl)-2,5-dimethylthiophen-3-yl]acetonitrile Chemical compound CC=1SC(C)=C(CC#N)C=1CCl FOIDGFDGJSUMLK-UHFFFAOYSA-N 0.000 description 3
- NLNLBKRQFKMSOF-UHFFFAOYSA-N 2-[4-[(4-bromophenoxy)methyl]-2,5-dimethylthiophen-3-yl]acetonitrile Chemical compound S1C(C)=C(CC#N)C(COC=2C=CC(Br)=CC=2)=C1C NLNLBKRQFKMSOF-UHFFFAOYSA-N 0.000 description 3
- CXPKYNLXLOGSCI-UHFFFAOYSA-N 2-[4-[(4-bromophenoxy)methyl]-2,5-dimethylthiophen-3-yl]ethanamine Chemical compound NCCC1=C(C)SC(C)=C1COC1=CC=C(Br)C=C1 CXPKYNLXLOGSCI-UHFFFAOYSA-N 0.000 description 3
- PVZNSLFECJBOBR-UHFFFAOYSA-N 4-[[4-carboxybutyl-[2-[3-[[4-(4-methoxyphenyl)phenyl]methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethyl]amino]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(C=C1)=CC=C1COC(C(=C1)CCN(CCCCC(O)=O)CC=2C=CC(=CC=2)C(O)=O)=CC2=C1CCCC2 PVZNSLFECJBOBR-UHFFFAOYSA-N 0.000 description 3
- XWHIZVSPBHOTDC-UHFFFAOYSA-N 6-[(4-bromophenyl)methoxy]-7-(chloromethyl)-1,2,3,4-tetrahydronaphthalene Chemical compound ClCC1=CC=2CCCCC=2C=C1OCC1=CC=C(Br)C=C1 XWHIZVSPBHOTDC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- DMSBTMWOBPXLNT-UHFFFAOYSA-N [3-[(4-bromophenyl)methoxy]-6-methylpyridin-2-yl]methanol Chemical compound OCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 DMSBTMWOBPXLNT-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- FEBRRXSUDPDMBK-UHFFFAOYSA-N methyl 3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalene-2-carboxylate Chemical compound COC(=O)C1=CC=2CCCCC=2C=C1OCC1=CC=C(Br)C=C1 FEBRRXSUDPDMBK-UHFFFAOYSA-N 0.000 description 3
- IJWWZCAMWZSCQB-UHFFFAOYSA-N methyl 4-[[(5-methoxy-5-oxopentyl)-[2-[3-[[4-(4-methoxyphenyl)phenyl]methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethyl]amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OC)CCC1=CC=2CCCCC=2C=C1OCC(C=C1)=CC=C1C1=CC=C(OC)C=C1 IJWWZCAMWZSCQB-UHFFFAOYSA-N 0.000 description 3
- BONOWYJMAGRYJI-UHFFFAOYSA-N methyl 4-[[(5-methoxy-5-oxopentyl)-[2-[3-[[4-[4-(trifluoromethyl)phenyl]phenyl]methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethyl]amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OC)CCC1=CC=2CCCCC=2C=C1OCC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 BONOWYJMAGRYJI-UHFFFAOYSA-N 0.000 description 3
- CRKMAHSFVOYLJL-UHFFFAOYSA-N methyl 4-[[2-[3-[(4-bromophenyl)methoxy]-5,6,7,8-tetrahydronaphthalen-2-yl]ethylamino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCCC(C(=C1)OCC=2C=CC(Br)=CC=2)=CC2=C1CCCC2 CRKMAHSFVOYLJL-UHFFFAOYSA-N 0.000 description 3
- UTZOPMKFAAMQRI-UHFFFAOYSA-N methyl 4-[[2-[3-[(4-bromophenyl)methoxy]-6-methylpyridin-2-yl]ethyl-(5-ethoxy-5-oxopentyl)amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OCC)CCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 UTZOPMKFAAMQRI-UHFFFAOYSA-N 0.000 description 3
- GFLOZIGMCRFGLU-UHFFFAOYSA-N methyl 4-[[2-[3-[(4-bromophenyl)methoxy]-6-methylpyridin-2-yl]ethylamino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCCC1=NC(C)=CC=C1OCC1=CC=C(Br)C=C1 GFLOZIGMCRFGLU-UHFFFAOYSA-N 0.000 description 3
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 3
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IPSRUMUXEPMQCS-UHFFFAOYSA-N (1-methoxycyclohexa-2,4-dien-1-yl)boronic acid Chemical compound COC1(B(O)O)CC=CC=C1 IPSRUMUXEPMQCS-UHFFFAOYSA-N 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 2
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CVQBAADHCLGLPU-UHFFFAOYSA-N 4-[[4-carboxybutyl-[2-[4-[[4-(2,4-dichlorophenyl)phenoxy]methyl]-2,5-dimethylthiophen-3-yl]ethyl]amino]methyl]benzoic acid Chemical compound C=1C=C(C(O)=O)C=CC=1CN(CCCCC(O)=O)CCC1=C(C)SC(C)=C1COC(C=C1)=CC=C1C1=CC=C(Cl)C=C1Cl CVQBAADHCLGLPU-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- OAHNDSLSKSVLLN-UHFFFAOYSA-N C.CC.C[V]C[Y].C[W]C Chemical compound C.CC.C[V]C[Y].C[W]C OAHNDSLSKSVLLN-UHFFFAOYSA-N 0.000 description 2
- BHYGASUDNMLIKF-ZPYUXNTASA-N C/C=C/[Ar].CCC1=CC=CC=C1 Chemical compound C/C=C/[Ar].CCC1=CC=CC=C1 BHYGASUDNMLIKF-ZPYUXNTASA-N 0.000 description 2
- VFAMWAQOWFZHHV-UHFFFAOYSA-N CC[Y] Chemical compound CC[Y] VFAMWAQOWFZHHV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 2
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 2
- 235000008718 isoliquiritigenin Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- YRGJVRHNWPDXMH-UHFFFAOYSA-N methyl 3-hydroxy-5,6,7,8-tetrahydronaphthalene-2-carboxylate Chemical compound C1CCCC2=C1C=C(C(=O)OC)C(O)=C2 YRGJVRHNWPDXMH-UHFFFAOYSA-N 0.000 description 2
- QDLIXOZFOPMCIT-UHFFFAOYSA-N methyl 4-[[2-[4-[(4-bromophenoxy)methyl]-2,5-dimethylthiophen-3-yl]ethyl-(5-ethoxy-5-oxopentyl)amino]methyl]benzoate Chemical compound C=1C=C(C(=O)OC)C=CC=1CN(CCCCC(=O)OCC)CCC1=C(C)SC(C)=C1COC1=CC=C(Br)C=C1 QDLIXOZFOPMCIT-UHFFFAOYSA-N 0.000 description 2
- YGBRFLVGHVQVKP-UHFFFAOYSA-N methyl 4-[[2-[4-[(4-bromophenoxy)methyl]-2,5-dimethylthiophen-3-yl]ethylamino]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CNCCC1=C(C)SC(C)=C1COC1=CC=C(Br)C=C1 YGBRFLVGHVQVKP-UHFFFAOYSA-N 0.000 description 2
- RAVVJKCSZXAIQP-UHFFFAOYSA-N methyl 5-bromopentanoate Chemical compound COC(=O)CCCCBr RAVVJKCSZXAIQP-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000002825 nitriles Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- QMMOXUPEWRXHJS-UHFFFAOYSA-N pent-2-ene Chemical group CCC=CC QMMOXUPEWRXHJS-UHFFFAOYSA-N 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N phenyl mercaptan Natural products SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Substances [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- OEUYDUFJRIQAMP-UHFFFAOYSA-N (1-fluorocyclohexa-2,4-dien-1-yl)boronic acid Chemical compound FC1(CC=CC=C1)B(O)O OEUYDUFJRIQAMP-UHFFFAOYSA-N 0.000 description 1
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1Cl QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 1
- VBHARLNUEDIKQD-UHFFFAOYSA-N (2-methoxynaphthalen-1-yl)methanol Chemical compound C1=CC=CC2=C(CO)C(OC)=CC=C21 VBHARLNUEDIKQD-UHFFFAOYSA-N 0.000 description 1
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- HLQZCRVEEQKNMS-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylbenzene Chemical group C1=CC(CCl)=CC=C1C1=CC=CC=C1 HLQZCRVEEQKNMS-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 1
- KXCLEESYGWKEHV-UHFFFAOYSA-N 2-(3-hydroxypyridin-2-yl)acetonitrile Chemical compound OC1=CC=CN=C1CC#N KXCLEESYGWKEHV-UHFFFAOYSA-N 0.000 description 1
- PAGTXDLKXRBHFL-UHFFFAOYSA-N 2-(hydroxymethyl)-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(CO)=N1 PAGTXDLKXRBHFL-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- NTCCNERMXRIPTR-UHFFFAOYSA-N 2-hydroxy-1-naphthaldehyde Chemical compound C1=CC=CC2=C(C=O)C(O)=CC=C21 NTCCNERMXRIPTR-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UOAVLAVHDBWBGV-UHFFFAOYSA-N 3,4-bis(chloromethyl)-2,5-dimethylthiophene Chemical compound CC=1SC(C)=C(CCl)C=1CCl UOAVLAVHDBWBGV-UHFFFAOYSA-N 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- GZFGOTFRPZRKDS-UHFFFAOYSA-N 4-bromophenol Chemical compound OC1=CC=C(Br)C=C1 GZFGOTFRPZRKDS-UHFFFAOYSA-N 0.000 description 1
- SIAVMDKGVRXFAX-UHFFFAOYSA-N 4-carboxyphenylboronic acid Chemical compound OB(O)C1=CC=C(C(O)=O)C=C1 SIAVMDKGVRXFAX-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical class OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CIMZEZRAUZRTBN-UHFFFAOYSA-N C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC=O.CC=O.CCC#N.CCCN.CCCl.CCO.CO.N#C[K].O=S(Cl)Cl Chemical compound C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC.CC=O.CC=O.CCC#N.CCCN.CCCl.CCO.CO.N#C[K].O=S(Cl)Cl CIMZEZRAUZRTBN-UHFFFAOYSA-N 0.000 description 1
- KGCXTTXHOAKLNA-UHFFFAOYSA-N C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC.CC=O.CC=O.CCC#N.CCCN.CCCl.CCO.CC[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].N#C[K].O=S(Cl)Cl Chemical compound C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC.CC=O.CC=O.CCC#N.CCCN.CCCl.CCO.CC[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].C[V]C[Y].N#C[K].O=S(Cl)Cl KGCXTTXHOAKLNA-UHFFFAOYSA-N 0.000 description 1
- BGLJRQHZWXMUOY-UHFFFAOYSA-N C.C.C.C.C.C.CC.CC.CC.CC.CC.CC(=O)Cl.CC=O.CCC#N.CCCN.CCO.CCOC(C)=O.CO.CO.CO.CO.COC(C)=O.N#C[K] Chemical compound C.C.C.C.C.C.CC.CC.CC.CC.CC.CC(=O)Cl.CC=O.CCC#N.CCCN.CCO.CCOC(C)=O.CO.CO.CO.CO.COC(C)=O.N#C[K] BGLJRQHZWXMUOY-UHFFFAOYSA-N 0.000 description 1
- RBKMFCMLZBFJCF-UHFFFAOYSA-N C.C.C.C.C.C.CC.CC.CC.CC.CC.CC=O.CCC#N.CCCN.CCCl.CCO.CO.CO.CO.CO.CO.N#C[K].O=S(Cl)Cl Chemical compound C.C.C.C.C.C.CC.CC.CC.CC.CC.CC=O.CCC#N.CCCN.CCCl.CCO.CO.CO.CO.CO.CO.N#C[K].O=S(Cl)Cl RBKMFCMLZBFJCF-UHFFFAOYSA-N 0.000 description 1
- IRBXDFCLQMGWJG-UHFFFAOYSA-N C.C.C.C.CC.CC.CC.CC.CC.CC.CC=C[N+](=O)[O-].CC=O.CCCN.C[N+](=O)[O-] Chemical compound C.C.C.C.CC.CC.CC.CC.CC.CC.CC=C[N+](=O)[O-].CC=O.CCCN.C[N+](=O)[O-] IRBXDFCLQMGWJG-UHFFFAOYSA-N 0.000 description 1
- WJARFKDOOOUEQY-BUQILDFBSA-N C.C.C.C.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.COCC1=CC=C(CCC2=CC=CC=C2)C=C1.COCC1=CC=C(CCC2=CC=CC=C2)C=C1.ClCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.[H]OC(=O)CCCCN(CCC)CC1=CC=C(C(=O)O[H])C=C1 Chemical compound C.C.C.C.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.COCC1=CC=C(CCC2=CC=CC=C2)C=C1.COCC1=CC=C(CCC2=CC=CC=C2)C=C1.ClCC1=CC=C(/C=C/C2=CC=CC=C2)C=C1.[H]OC(=O)CCCCN(CCC)CC1=CC=C(C(=O)O[H])C=C1 WJARFKDOOOUEQY-BUQILDFBSA-N 0.000 description 1
- JKINWEUBUIUUAR-UHFFFAOYSA-N C.C.C.CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(C)=O)CC1=CC=C(C(=O)OC)C=C1.COC(=O)C1=CC=C(CBr)C=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.[H]N(CCC)CCCCC(C)=O Chemical compound C.C.C.CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(C)=O)CC1=CC=C(C(=O)OC)C=C1.COC(=O)C1=CC=C(CBr)C=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.[H]N(CCC)CCCCC(C)=O JKINWEUBUIUUAR-UHFFFAOYSA-N 0.000 description 1
- ZJSZZKLNKWQKQU-UHFFFAOYSA-N C.C1=CC2=C(C=C1)OC=N2.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNCC1.C1CNCCN1.C1COCCN1 Chemical compound C.C1=CC2=C(C=C1)OC=N2.C1=CC=NC=C1.C1=CC=NN=C1.C1=CN=CC=N1.C1=CN=CN=C1.C1=CNC=C1.C1=CNC=N1.C1=COC=C1.C1=COC=N1.C1=CSC=C1.C1=CSC=N1.C1=CSN=N1.C1=NC=NO1.C1=NC=NS1.C1CCNCC1.C1CNCCN1.C1COCCN1 ZJSZZKLNKWQKQU-UHFFFAOYSA-N 0.000 description 1
- SFLZJHRAUWJSFR-UHFFFAOYSA-N C.CC.CC.CC.CC.CCC#N.CCCN.CCC[Y].CCC[Y].CCCl.CCCl.CCCl.CCCl.CC[Y] Chemical compound C.CC.CC.CC.CC.CCC#N.CCCN.CCC[Y].CCC[Y].CCCl.CCCl.CCCl.CCCl.CC[Y] SFLZJHRAUWJSFR-UHFFFAOYSA-N 0.000 description 1
- NITJLMSEFNROAC-UHFFFAOYSA-N C.C[Si](C)(C)Cl.C[Si](C)(C)OC1=CC=CN=C1CC#N.C[Si](C)(C)OC1=CC=CN=C1CCN.N#CCC1=NC=CC=C1O.N#C[K].OC1=CC=CN=C1CCl.OCC1=NC=CC=C1O Chemical compound C.C[Si](C)(C)Cl.C[Si](C)(C)OC1=CC=CN=C1CC#N.C[Si](C)(C)OC1=CC=CN=C1CCN.N#CCC1=NC=CC=C1O.N#C[K].OC1=CC=CN=C1CCl.OCC1=NC=CC=C1O NITJLMSEFNROAC-UHFFFAOYSA-N 0.000 description 1
- RXKVOOACNOIKQO-UHFFFAOYSA-N C.ClCC1=CC=CN=C1[V]C[Y].N#CCC1=CC=CN=C1[V]C[Y].N#C[K].NCCC1=CC=CN=C1[V]C[Y].O=C(O)C1=CC=CN=C1Cl.O=C(O)C1=CC=CN=C1[V]C[Y].O=P(Cl)(Cl)Cl.OCC1=CC=CN=C1[V]C[Y].[AlH3].[H][V]C[Y].[LiH] Chemical compound C.ClCC1=CC=CN=C1[V]C[Y].N#CCC1=CC=CN=C1[V]C[Y].N#C[K].NCCC1=CC=CN=C1[V]C[Y].O=C(O)C1=CC=CN=C1Cl.O=C(O)C1=CC=CN=C1[V]C[Y].O=P(Cl)(Cl)Cl.OCC1=CC=CN=C1[V]C[Y].[AlH3].[H][V]C[Y].[LiH] RXKVOOACNOIKQO-UHFFFAOYSA-N 0.000 description 1
- JYTYKEGYUOJJRO-UHFFFAOYSA-N CC(=O)CBr.CC(=O)CN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.COC(=O)CCCCN(CC(C)=O)CC1=CC=C(C(=O)OC)C=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.[H]N(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1 Chemical compound CC(=O)CBr.CC(=O)CN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.COC(=O)CCCCN(CC(C)=O)CC1=CC=C(C(=O)OC)C=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.COCC1=CC=CC=C1.[H]N(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1 JYTYKEGYUOJJRO-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N CC(C)=O Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- SGQUPAAFPTZLHE-UHFFFAOYSA-N CC.CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=C(Cl)C=CC=C1.COCC1=C(Cl)C=CC=C1 Chemical compound CC.CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=C(Cl)C=CC=C1.COCC1=C(Cl)C=CC=C1 SGQUPAAFPTZLHE-UHFFFAOYSA-N 0.000 description 1
- PYFLTKNJZIIIGF-UHFFFAOYSA-N CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(=O)O)C=C3)C=C2)=C(C)S1 Chemical compound CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(=O)O)C=C3)C=C2)=C(C)S1 PYFLTKNJZIIIGF-UHFFFAOYSA-N 0.000 description 1
- ZUVVITWXXHLINS-UHFFFAOYSA-N CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(C)(C)C)C=C3)C=C2)=C(C)S1 Chemical compound CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(C)(C)C)C=C3)C=C2)=C(C)S1 ZUVVITWXXHLINS-UHFFFAOYSA-N 0.000 description 1
- XFWWFBAYPBVZCS-UHFFFAOYSA-N CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=C(C)S1 Chemical compound CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=C(C)S1 XFWWFBAYPBVZCS-UHFFFAOYSA-N 0.000 description 1
- VWTSKWIQAAVOFD-UHFFFAOYSA-N CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(Cl)C=C3)C=C2)=C(C)S1 Chemical compound CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(Cl)C=C3)C=C2)=C(C)S1 VWTSKWIQAAVOFD-UHFFFAOYSA-N 0.000 description 1
- FCAKLYIGGLEJBD-UHFFFAOYSA-N CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(F)C=C3)C=C2)=C(C)S1 Chemical compound CC1=C(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)C(COC2=CC=C(C3=CC=C(F)C=C3)C=C2)=C(C)S1 FCAKLYIGGLEJBD-UHFFFAOYSA-N 0.000 description 1
- LYJNZBNLGMBPJI-UHFFFAOYSA-N CC1=NC(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C=C1 Chemical compound CC1=NC(CCN(CCCCC(=O)O)CC2=CC=C(C(=O)O)C=C2)=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C=C1 LYJNZBNLGMBPJI-UHFFFAOYSA-N 0.000 description 1
- XPVQNVGQWFDZPC-UHFFFAOYSA-N CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=CC=C(Br)C=C1.COCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.COCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.ClCC1=CC=C(Br)C=C1.OB(O)C1=CC=C(Cl)C=C1 Chemical compound CCCN(CCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCN(CCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CO.COCC1=CC=C(Br)C=C1.COCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.COCC1=CC=C(C2=CC=C(Cl)C=C2)C=C1.ClCC1=CC=C(Br)C=C1.OB(O)C1=CC=C(Cl)C=C1 XPVQNVGQWFDZPC-UHFFFAOYSA-N 0.000 description 1
- AIGCZQNPOWXPMM-UHFFFAOYSA-N CCCN(CCCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCNCC1=CC=C(C(=O)OC)C=C1.COC(=O)CCCCCCBr.COCCCCCC1=CC=CC=C1.COCCCCCC1=CC=CC=C1.COCCCCCC1=CC=CC=C1 Chemical compound CCCN(CCCCCC(=O)O)CC1=CC=C(C(=O)O)C=C1.CCCN(CCCCCC(=O)OC)CC1=CC=C(C(=O)OC)C=C1.CCCNCC1=CC=C(C(=O)OC)C=C1.COC(=O)CCCCCCBr.COCCCCCC1=CC=CC=C1.COCCCCCC1=CC=CC=C1.COCCCCCC1=CC=CC=C1 AIGCZQNPOWXPMM-UHFFFAOYSA-N 0.000 description 1
- LQOZKQHLJUSINB-UHFFFAOYSA-N COC(=O)C1=C(O)C2=CC(OC)=CC=C2N1C.O=C(O)C1=C(O)C=CC2=C1NC1=C2C=CC=C1.O=C(O)C1=CC2=C(C=C1O)NC1=C2C=CC=C1.O=C(O)C1=CC=CN=C1O.OCC1=NC=CC=C1O Chemical compound COC(=O)C1=C(O)C2=CC(OC)=CC=C2N1C.O=C(O)C1=C(O)C=CC2=C1NC1=C2C=CC=C1.O=C(O)C1=CC2=C(C=C1O)NC1=C2C=CC=C1.O=C(O)C1=CC=CN=C1O.OCC1=NC=CC=C1O LQOZKQHLJUSINB-UHFFFAOYSA-N 0.000 description 1
- JYCCNSVITVTALB-UHFFFAOYSA-N COC(=O)CCCCN(CCC1=C(C)SC(C)=C1COC1=CC=C(Br)C=C1)CC1=CC=C(C(=O)OC)C=C1 Chemical compound COC(=O)CCCCN(CCC1=C(C)SC(C)=C1COC1=CC=C(Br)C=C1)CC1=CC=C(C(=O)OC)C=C1 JYCCNSVITVTALB-UHFFFAOYSA-N 0.000 description 1
- VVWXMKMOENJRDG-UHFFFAOYSA-N COC(=O)CCCCN(CCC1=C(C)SC(C)=C1COC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1)CC1=CC=C(C(=O)OC)C=C1 Chemical compound COC(=O)CCCCN(CCC1=C(C)SC(C)=C1COC1=CC=C(C2=CC=C(Cl)C=C2Cl)C=C1)CC1=CC=C(C(=O)OC)C=C1 VVWXMKMOENJRDG-UHFFFAOYSA-N 0.000 description 1
- UFROICUDKVGJPR-UHFFFAOYSA-N COC1=CC(C2=CC=C(OCC3=C(C)SC(C)=C3CCN(CCCCC(=O)O)CC3=CC=C(C(=O)O)C=C3)C=C2)=CC=C1 Chemical compound COC1=CC(C2=CC=C(OCC3=C(C)SC(C)=C3CCN(CCCCC(=O)O)CC3=CC=C(C(=O)O)C=C3)C=C2)=CC=C1 UFROICUDKVGJPR-UHFFFAOYSA-N 0.000 description 1
- MGDIPJLRCUVUEY-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(OCC3=C(C)SC(C)=C3CCN(CCCCC(=O)O)CC3=CC=C(C(=O)O)C=C3)C=C2)C=C1 Chemical compound COC1=CC=C(C2=CC=C(OCC3=C(C)SC(C)=C3CCN(CCCCC(=O)O)CC3=CC=C(C(=O)O)C=C3)C=C2)C=C1 MGDIPJLRCUVUEY-UHFFFAOYSA-N 0.000 description 1
- XZJUULRASGPEAU-UHFFFAOYSA-N COC1=CC=C(CN(CCCCC(=O)O)CC2=CC=C(OC)C=C2)C=C1 Chemical compound COC1=CC=C(CN(CCCCC(=O)O)CC2=CC=C(OC)C=C2)C=C1 XZJUULRASGPEAU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- VFDPQZFQILFRSY-UHFFFAOYSA-N O=C(O)CCCCN(CC1=CC=CC=C1)CC1=CC=CC=C1 Chemical compound O=C(O)CCCCN(CC1=CC=CC=C1)CC1=CC=CC=C1 VFDPQZFQILFRSY-UHFFFAOYSA-N 0.000 description 1
- CEVNZGLIKKMCMF-UHFFFAOYSA-N O=C(O)CCCCN(CCC1=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C=C2CCCCC2=C1)CC1=CC=C(C(=O)O)C=C1 Chemical compound O=C(O)CCCCN(CCC1=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C=C2CCCCC2=C1)CC1=CC=C(C(=O)O)C=C1 CEVNZGLIKKMCMF-UHFFFAOYSA-N 0.000 description 1
- SHAVACKPMLKISZ-UHFFFAOYSA-N O=CC1=CC=C2C=CC=CC2=C1O.OC=C1=C(O)C2=C(C=CC=N2)C=C1 Chemical compound O=CC1=CC=C2C=CC=CC2=C1O.OC=C1=C(O)C2=C(C=CC=N2)C=C1 SHAVACKPMLKISZ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007786 learning performance Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- MGMWQSVSOGNGPL-UHFFFAOYSA-N methyl 2-bromopentanoate Chemical compound CCCC(Br)C(=O)OC MGMWQSVSOGNGPL-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical class [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000006578 reductive coupling reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910000161 silver phosphate Inorganic materials 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 229960000340 thiopental sodium Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical class CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/581,261 US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10110750.1 | 2001-03-07 | ||
| DE10110750A DE10110750A1 (de) | 2001-03-07 | 2001-03-07 | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| PCT/EP2002/001891 WO2002070510A2 (de) | 2001-03-07 | 2002-02-22 | Aminodicarbonsäurederivate mit pharmazeutischen eigenschaften |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/581,261 Continuation US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040082798A1 true US20040082798A1 (en) | 2004-04-29 |
Family
ID=7676478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/469,817 Abandoned US20040082798A1 (en) | 2001-03-07 | 2002-02-22 | Novel amino dicarboxylic acid derivatives with pharmaceutical properties |
| US11/581,261 Expired - Fee Related US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/581,261 Expired - Fee Related US7705043B2 (en) | 2001-03-07 | 2006-10-10 | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040082798A1 (ja) |
| EP (1) | EP1368335A2 (ja) |
| JP (1) | JP4535679B2 (ja) |
| AU (1) | AU2002234645A1 (ja) |
| CA (1) | CA2439756C (ja) |
| DE (1) | DE10110750A1 (ja) |
| WO (1) | WO2002070510A2 (ja) |
Cited By (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009870A1 (en) * | 2003-07-11 | 2005-01-13 | Sher Philip M. | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20050282820A1 (en) * | 2004-06-17 | 2005-12-22 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US20050288366A1 (en) * | 2001-03-01 | 2005-12-29 | Bayer Aktiengesellschaft | Novel aminodicarboxylic acid derivatives |
| US20060111355A1 (en) * | 2004-11-23 | 2006-05-25 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20060189618A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189616A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189617A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060264631A1 (en) * | 2005-05-18 | 2006-11-23 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US20060270848A1 (en) * | 2005-05-26 | 2006-11-30 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| US20070135477A1 (en) * | 2003-07-03 | 2007-06-14 | Astex Therapeuctics, Limited | Benzimidazole derivatives and their use as protein kinases inhibitors |
| US20070225318A1 (en) * | 2004-09-20 | 2007-09-27 | Biolipox Ab | Pyrazole Compounds Useful In The Treatment Of Inflammation |
| US20080071095A1 (en) * | 2004-06-24 | 2008-03-20 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| US20080081821A1 (en) * | 2006-08-21 | 2008-04-03 | Genentech, Inc. | AZA-benzothiophenyl compounds and methods of use |
| US20080085886A1 (en) * | 2006-08-21 | 2008-04-10 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| US20080132495A1 (en) * | 2004-12-30 | 2008-06-05 | Astex Therapeutics Limited | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases |
| US20090088463A1 (en) * | 2005-11-01 | 2009-04-02 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| US20090143440A1 (en) * | 2005-10-31 | 2009-06-04 | Biolipox Ab | Pyrazoles Useful in the Treatment of Inflammation |
| US20090143455A1 (en) * | 2005-10-20 | 2009-06-04 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
| US20090186918A1 (en) * | 2005-10-31 | 2009-07-23 | Benjamin Pelcman | Triazole Compounds as Lipoxygenase Inhibitors |
| US20090215843A1 (en) * | 2005-10-21 | 2009-08-27 | Stephan Bartel | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases |
| US20090227640A1 (en) * | 2005-10-21 | 2009-09-10 | Bayer Healthcare Ag | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases |
| US20090286882A1 (en) * | 2005-10-21 | 2009-11-19 | Bayer Healthcare Ag | Cyclopropylacetic Acid Derivatives and Use Thereof |
| US20090291993A1 (en) * | 2005-10-21 | 2009-11-26 | Stephan Bartel | Difluorophenol Derivatives and Their Use |
| US20100029772A1 (en) * | 2005-10-21 | 2010-02-04 | Stephan Bartel | Dicarboxylic Acid Derivatives and their Use |
| US7696210B2 (en) | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US20100168240A1 (en) * | 2007-03-29 | 2010-07-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
| US20100184739A1 (en) * | 2004-06-24 | 2010-07-22 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| US20100197680A1 (en) * | 2007-03-29 | 2010-08-05 | Michael Hahn | Lactam-substituted dicarboxylic acids and use thereof |
| US20100234432A1 (en) * | 2007-09-07 | 2010-09-16 | Bayer Animal Health Gmbh | Substituted 6-phenylnicotinic acids and their use |
| US20100261698A1 (en) * | 2008-06-27 | 2010-10-14 | Christopher Adams | Organic compounds |
| US20110064811A1 (en) * | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20110159474A1 (en) * | 2007-06-06 | 2011-06-30 | Bayer Schering Pharma Aktiengesellschaft | Solutions for perfusing and preserving organs and tissues |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8435970B2 (en) | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
| US8673903B2 (en) | 2010-05-14 | 2014-03-18 | Bayer Intellectual Property Gmbh | Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof |
| US8796324B2 (en) | 2009-03-18 | 2014-08-05 | Bayer Intellectual Property Gmbh | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US8859601B2 (en) | 2008-12-06 | 2014-10-14 | Bayer Intellectual Property Gmbh | Substituted benzyl and phenylsulfonyl triazolones, and use thereof |
| US8981104B2 (en) | 2012-07-20 | 2015-03-17 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| US9034855B2 (en) | 2010-09-16 | 2015-05-19 | Bayer Intellectual Property Gmbh | Substituted phenylacetate and phenylpropane amides and use thereof |
| US9180120B2 (en) | 2010-09-02 | 2015-11-10 | Bayer Intellectual Property Gmbh | Substituted N-phenethyltriazoloneacetamides and use thereof |
| US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| CN105658621A (zh) * | 2013-10-15 | 2016-06-08 | 东亚荣养株式会社 | 4-氨甲基苯甲酸衍生物 |
| US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US9771352B2 (en) | 2014-11-03 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10336749B2 (en) | 2015-08-21 | 2019-07-02 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
| US10414765B2 (en) | 2015-12-10 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
| US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10722501B2 (en) | 2016-05-09 | 2020-07-28 | Bayer Aktiengesellschaft | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof |
| US10759794B2 (en) | 2015-12-10 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
| US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
| US11098063B2 (en) | 2017-06-14 | 2021-08-24 | Bayer Aktiengesellschaft | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders |
| US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11166932B2 (en) | 2015-07-23 | 2021-11-09 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof |
| US11173151B2 (en) | 2017-10-24 | 2021-11-16 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11298367B2 (en) | 2017-10-24 | 2022-04-12 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
| US11331314B2 (en) | 2017-10-24 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
| DE10216145A1 (de) * | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DK1644336T3 (da) | 2003-06-06 | 2011-05-09 | Fibrogen Inc | Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
| DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
| BRPI0518096A (pt) | 2004-12-01 | 2008-10-28 | Kalypsys Inc | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos |
| KR101345002B1 (ko) | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| JP5475235B2 (ja) | 2005-01-21 | 2014-04-16 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| EP2476669A1 (en) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
| JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン， インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
| DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
| DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
| DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
| DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
| DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
| DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
| US8309596B2 (en) | 2007-06-28 | 2012-11-13 | Novartis Ag | Kallikrein 7 modulators |
| DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
| DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
| DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
| DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
| DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
| DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
| DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
| DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
| JP5432890B2 (ja) | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
| ES2428818T3 (es) * | 2008-05-29 | 2013-11-11 | Bayer Intellectual Property Gmbh | Dicianopiridinas sustituidas con 2-alcoxi y su uso |
| DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
| DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
| DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
| DE102008054205A1 (de) | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
| WO2010056767A1 (en) | 2008-11-14 | 2010-05-20 | Fibrogen, Inc. | Thiochromene derivatives as hip hydroxylase inhibitors |
| DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
| DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
| DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| HUE025162T2 (en) | 2010-05-26 | 2016-04-28 | Adverio Pharma Gmbh | Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc). |
| DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
| CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| ES2622519T3 (es) | 2010-07-14 | 2017-07-06 | Novartis Ag | Componentes heterocíclicos agonistas del receptor IP |
| US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| MX2014000031A (es) | 2011-07-01 | 2014-07-09 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos. |
| CA2840944A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
| EP2802582A1 (en) | 2012-01-13 | 2014-11-19 | Novartis AG | Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| US20140378463A1 (en) | 2012-01-13 | 2014-12-25 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| WO2013105066A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Salts of an ip receptor agonist |
| WO2013105063A1 (en) | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| ES2565826T3 (es) | 2012-01-13 | 2016-04-07 | Novartis Ag | Pirroles fusionados como agonistas del receptor IP para el tratamiento de hipertensión arterial pulmonar (PAH) y trastornos relacionados |
| WO2013134660A1 (en) | 2012-03-09 | 2013-09-12 | Fibrogen, Inc. | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
| UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| WO2014014834A1 (en) | 2012-07-16 | 2014-01-23 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| EP3470397B1 (en) | 2012-07-16 | 2021-12-29 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| DK2951159T3 (en) | 2013-01-24 | 2018-11-19 | Fibrogen Inc | CRYSTALLIC FORMS OF {[1-CYANO-5- (4-CHLORPHENOXY) -4-HYDROXY-ISOQUINOLIN-3-CARBONYL] -AMINO} ACETIC ACID |
| US9604981B2 (en) | 2013-02-13 | 2017-03-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| US10265314B2 (en) | 2013-07-25 | 2019-04-23 | Bayer Pharma Aktiengesellschaft | SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis |
| WO2015036563A1 (de) | 2013-09-16 | 2015-03-19 | Bayer Pharma Aktiengesellschaft | Disubstituierte trifluormethylpyrimidinone und ihre verwendung als ccr2 antagonisten |
| AU2014334040A1 (en) | 2013-10-07 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Cyclic thienouracil-carboxamides and use thereof |
| WO2015067630A1 (de) | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
| JP2016535769A (ja) | 2013-11-08 | 2016-11-17 | バイエル ファーマ アクチエンゲゼルシャフト | キマーゼ阻害薬としての置換されているウラシル類 |
| JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α２Ｃ拮抗薬としての置換されたビピペリジニル誘導体 |
| AP2016009303A0 (en) | 2013-12-19 | 2016-06-30 | Bayer Pharma AG | Substituted piperidinyl-tetrahydroquinolines |
| EP3083594A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten |
| JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
| WO2015150350A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
| EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
| CA2945257A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯－１－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩－２－基－吡啶－２－基－１ｈ－吡唑－４－羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| USRE49575E1 (en) | 2014-08-01 | 2023-07-11 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| WO2016113205A1 (de) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Substituierte pentafluorethylpyrimidinone und ihre verwendung |
| UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| KR20180002657A (ko) | 2015-05-06 | 2018-01-08 | 바이엘 파마 악티엔게젤샤프트 | 전신 경화증 (SSc)에 수반되는 수족지 궤양 (DU)의 치료를 위한 sGC 자극제, sGC 활성화제 단독 및 PDE5 억제제와의 조합물의 용도 |
| US20190008867A1 (en) | 2015-11-13 | 2019-01-10 | Ph Pharma Co., Ltd. | 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds |
| WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
| WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
| WO2017191105A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
| JP6911052B2 (ja) | 2016-05-03 | 2021-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | オキソアルキル置換フェニルトリアゾール誘導体およびその使用 |
| EP3452470B1 (en) | 2016-05-03 | 2020-03-18 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
| EP3452472A1 (en) | 2016-05-03 | 2019-03-13 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
| CA3030204A1 (en) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
| EP3296298A1 (de) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| US20200016159A1 (en) | 2016-09-23 | 2020-01-16 | Bayer Aktiengesellschaft | N3-cyclically substituted thienouracils and use thereof |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| EP3338803A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| EP3338764A1 (de) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische darreichungsformen enthaltend inhibitoren von task-1 und task-3 kanälen und deren verwendung für die therapie von atemstörungen |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| SG11201907209QA (en) | 2017-02-08 | 2019-09-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| EA201992386A1 (ru) | 2017-04-10 | 2020-03-27 | Байер Акциенгезельшафт | Замещенные n-арилэтил-2-арилхинолин-4-карбоксамиды и их применение |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| NZ762985A (en) | 2017-09-22 | 2024-03-22 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| HUE061607T2 (hu) | 2017-10-18 | 2023-07-28 | Jubilant Epipad LLC | Imidazopiridin vegyületek mint PAD inhibitorok |
| WO2019081291A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF |
| CA3084411A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| CN111386265A (zh) | 2017-11-06 | 2020-07-07 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物 |
| WO2019091847A1 (de) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | Substituierte 2,4-dihydro-3h-1,2,4-triazol-3-one und ihre verwendung |
| EP3704120B1 (en) | 2017-11-24 | 2024-03-06 | Jubilant Episcribe LLC | Heterocyclic compounds as prmt5 inhibitors |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| BR112020018610A2 (pt) | 2018-03-13 | 2020-12-29 | Jubilant Prodel LLC | Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas |
| EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
| EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
| EA202092779A1 (ru) | 2018-05-17 | 2021-02-02 | Байер Акциенгезельшафт | Замещенные дигидропиразолопиразинкарбоксамидные производные |
| CA3100271A1 (en) | 2018-05-22 | 2019-11-28 | Sunshine Lake Pharma Co., Ltd. | Phenyl-substituted dihydronaphthyridine compound and use thereof |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| JOP20210121A1 (ar) | 2018-11-27 | 2023-01-30 | Bayer Ag | عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة task-1 و task-3، واستخدامها في علاج اضطراب التنفس |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020165031A1 (de) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
| CN114793434A (zh) | 2019-10-18 | 2022-07-26 | 加利福尼亚大学董事会 | 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 |
| CN114702427A (zh) | 2019-10-25 | 2022-07-05 | 年衍药业(珠海)有限公司 | 吡咯酰胺类化合物及其用途 |
| AU2020377470A1 (en) | 2019-11-06 | 2022-05-26 | Bayer Aktiengesellschaft | Inhibitors of adrenoreceptor ADRAC2 |
| WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
| WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
| EP4106741A1 (en) | 2020-02-21 | 2022-12-28 | Universiteit Maastricht | Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme |
| CA3170508A1 (en) | 2020-02-26 | 2021-09-02 | Universiteit Maastricht | Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia |
| WO2022112213A1 (en) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
| WO2022122916A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
| EP4011873A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CA3204495A1 (en) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN115175681A (zh) | 2020-12-10 | 2022-10-11 | 拜耳公司 | sGC活化剂用于治疗眼科疾病的用途 |
| CN113563250B (zh) * | 2021-07-28 | 2023-07-07 | 南华大学 | 一种苯甲酸色胺衍生物及其制备与应用 |
| WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997029074A1 (fr) * | 1996-02-07 | 1997-08-14 | Banyu Pharmaceutical Co., Ltd. | Derives d'acides d'amides n,n-disubstitues |
| NZ513449A (en) * | 1999-03-01 | 2004-02-27 | Pfizer Prod Inc | Oxamic acids and derivatives as thyroid receptor ligands |
| FR2794742B1 (fr) * | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
-
2001
- 2001-03-07 DE DE10110750A patent/DE10110750A1/de not_active Withdrawn
-
2002
- 2002-02-22 WO PCT/EP2002/001891 patent/WO2002070510A2/de active Application Filing
- 2002-02-22 EP EP02701292A patent/EP1368335A2/de not_active Withdrawn
- 2002-02-22 CA CA2439756A patent/CA2439756C/en not_active Expired - Fee Related
- 2002-02-22 AU AU2002234645A patent/AU2002234645A1/en not_active Abandoned
- 2002-02-22 JP JP2002569830A patent/JP4535679B2/ja not_active Expired - Fee Related
- 2002-02-22 US US10/469,817 patent/US20040082798A1/en not_active Abandoned
-
2006
- 2006-10-10 US US11/581,261 patent/US7705043B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
Cited By (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288366A1 (en) * | 2001-03-01 | 2005-12-29 | Bayer Aktiengesellschaft | Novel aminodicarboxylic acid derivatives |
| US7329777B2 (en) * | 2001-03-01 | 2008-02-12 | Bayer Aktiengesellschaft | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis |
| US20110224203A1 (en) * | 2003-07-03 | 2011-09-15 | Astex Therapeutics Limited | Benzimidazole derivatives and their use as protein kinase inhibitors |
| US7977477B2 (en) | 2003-07-03 | 2011-07-12 | Astex Therapeutics, Limited | Benzimidazole derivatives and their use as protein kinase inhibitors |
| US20070135477A1 (en) * | 2003-07-03 | 2007-06-14 | Astex Therapeuctics, Limited | Benzimidazole derivatives and their use as protein kinases inhibitors |
| US7884113B2 (en) | 2003-07-11 | 2011-02-08 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20050014786A1 (en) * | 2003-07-11 | 2005-01-20 | Chongqing Sun | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US8119808B2 (en) | 2003-07-11 | 2012-02-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20050009870A1 (en) * | 2003-07-11 | 2005-01-13 | Sher Philip M. | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20110104315A1 (en) * | 2003-07-11 | 2011-05-05 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20080194625A1 (en) * | 2003-07-11 | 2008-08-14 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US20050282820A1 (en) * | 2004-06-17 | 2005-12-22 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US7714130B2 (en) | 2004-06-17 | 2010-05-11 | Wyeth | Processes for preparing gonadotropin releasing hormone receptor antagonists |
| US7696210B2 (en) | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US20100184739A1 (en) * | 2004-06-24 | 2010-07-22 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| US10662192B2 (en) | 2004-06-24 | 2020-05-26 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US9090619B2 (en) | 2004-06-24 | 2015-07-28 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8629162B2 (en) | 2004-06-24 | 2014-01-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US20090227797A1 (en) * | 2004-06-24 | 2009-09-10 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7495103B2 (en) | 2004-06-24 | 2009-02-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8829204B2 (en) | 2004-06-24 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US20080071095A1 (en) * | 2004-06-24 | 2008-03-20 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| US8101767B2 (en) | 2004-06-24 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8614327B2 (en) | 2004-06-24 | 2013-12-24 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8324242B2 (en) | 2004-06-24 | 2012-12-04 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US8741925B2 (en) | 2004-06-24 | 2014-06-03 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US20070225318A1 (en) * | 2004-09-20 | 2007-09-27 | Biolipox Ab | Pyrazole Compounds Useful In The Treatment Of Inflammation |
| US20060111355A1 (en) * | 2004-11-23 | 2006-05-25 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US8778936B2 (en) | 2004-12-30 | 2014-07-15 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
| US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
| US20080132495A1 (en) * | 2004-12-30 | 2008-06-05 | Astex Therapeutics Limited | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases |
| US20060189618A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189617A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189616A1 (en) * | 2005-02-18 | 2006-08-24 | Wyeth | 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20060264631A1 (en) * | 2005-05-18 | 2006-11-23 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US20060270848A1 (en) * | 2005-05-26 | 2006-11-30 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
| US20090143455A1 (en) * | 2005-10-20 | 2009-06-04 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
| US8173704B2 (en) | 2005-10-21 | 2012-05-08 | Bayer Pharma Aktiengesellschaft | Difluorophenol derivatives and their use |
| US20090286882A1 (en) * | 2005-10-21 | 2009-11-19 | Bayer Healthcare Ag | Cyclopropylacetic Acid Derivatives and Use Thereof |
| US8609727B2 (en) | 2005-10-21 | 2013-12-17 | Bayer Intellectual Property Gmbh | Dicarboxylic acid derivatives and their use |
| US20090227640A1 (en) * | 2005-10-21 | 2009-09-10 | Bayer Healthcare Ag | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases |
| US20090215843A1 (en) * | 2005-10-21 | 2009-08-27 | Stephan Bartel | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases |
| US8183271B2 (en) | 2005-10-21 | 2012-05-22 | Bayer Intellectual Property Gmbh | Tetrazole derivatives and their use for the treatment of cardiovascular diseases |
| US20090291993A1 (en) * | 2005-10-21 | 2009-11-26 | Stephan Bartel | Difluorophenol Derivatives and Their Use |
| US8168821B2 (en) | 2005-10-21 | 2012-05-01 | Bayer Pharma Aktiengesellschaft | Cyclopropylacetic acid derivatives and use thereof |
| US7998988B2 (en) | 2005-10-21 | 2011-08-16 | Bayer Schering Pharma Aktiengellschaft | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders |
| US20100029772A1 (en) * | 2005-10-21 | 2010-02-04 | Stephan Bartel | Dicarboxylic Acid Derivatives and their Use |
| US20090143440A1 (en) * | 2005-10-31 | 2009-06-04 | Biolipox Ab | Pyrazoles Useful in the Treatment of Inflammation |
| US20090186918A1 (en) * | 2005-10-31 | 2009-07-23 | Benjamin Pelcman | Triazole Compounds as Lipoxygenase Inhibitors |
| US20090088463A1 (en) * | 2005-11-01 | 2009-04-02 | Benjamin Pelcman | Pyrazoles Useful in the Treatment of Inflammation |
| US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| US9670163B2 (en) | 2005-12-28 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9139530B2 (en) | 2005-12-28 | 2015-09-22 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20110064811A1 (en) * | 2005-12-28 | 2011-03-17 | Patricia Hurter | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9931334B2 (en) | 2005-12-28 | 2018-04-03 | Vertex Pharmaceuticals Incorporated | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8754224B2 (en) | 2005-12-28 | 2014-06-17 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US10537565B2 (en) | 2005-12-28 | 2020-01-21 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8410274B2 (en) | 2005-12-28 | 2013-04-02 | Vertex Pharmaceuticals | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US11291662B2 (en) | 2005-12-28 | 2022-04-05 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8399442B2 (en) | 2005-12-30 | 2013-03-19 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US20110159111A1 (en) * | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8435970B2 (en) | 2006-06-29 | 2013-05-07 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
| US20080085886A1 (en) * | 2006-08-21 | 2008-04-10 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| US20080081821A1 (en) * | 2006-08-21 | 2008-04-03 | Genentech, Inc. | AZA-benzothiophenyl compounds and methods of use |
| US7893085B2 (en) | 2006-08-21 | 2011-02-22 | Genentech, Inc | Aza-benzothiophenyl compounds and methods of use |
| US20100168240A1 (en) * | 2007-03-29 | 2010-07-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
| US20100197680A1 (en) * | 2007-03-29 | 2010-08-05 | Michael Hahn | Lactam-substituted dicarboxylic acids and use thereof |
| US8217063B2 (en) | 2007-03-29 | 2012-07-10 | Bayer Intellectual Property Gmbh | Lactam-substituted dicarboxylic acids and use thereof |
| US7985876B2 (en) | 2007-03-29 | 2011-07-26 | Bayer Schering Pharma Aktiengesellschaft | Substituted dibenzoic acid derivatives and use thereof |
| US20110159474A1 (en) * | 2007-06-06 | 2011-06-30 | Bayer Schering Pharma Aktiengesellschaft | Solutions for perfusing and preserving organs and tissues |
| US20100234432A1 (en) * | 2007-09-07 | 2010-09-16 | Bayer Animal Health Gmbh | Substituted 6-phenylnicotinic acids and their use |
| US8143411B2 (en) | 2007-09-07 | 2012-03-27 | Bayer Animal Health Gmbh | Substituted 6-phenylnicotinic acids and their use |
| US20110082129A1 (en) * | 2008-06-27 | 2011-04-07 | Christopher Adams | Organic compounds |
| US9242963B2 (en) | 2008-06-27 | 2016-01-26 | Novartis Ag | Organic compounds |
| US8791141B2 (en) | 2008-06-27 | 2014-07-29 | Novartis Ag | Organic compounds |
| US20100261698A1 (en) * | 2008-06-27 | 2010-10-14 | Christopher Adams | Organic compounds |
| US8030334B2 (en) | 2008-06-27 | 2011-10-04 | Novartis Ag | Organic compounds |
| US10646481B2 (en) | 2008-08-13 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US11564916B2 (en) | 2008-08-13 | 2023-01-31 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8859601B2 (en) | 2008-12-06 | 2014-10-14 | Bayer Intellectual Property Gmbh | Substituted benzyl and phenylsulfonyl triazolones, and use thereof |
| US8796324B2 (en) | 2009-03-18 | 2014-08-05 | Bayer Intellectual Property Gmbh | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof |
| US9751839B2 (en) | 2009-03-20 | 2017-09-05 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US9187466B2 (en) | 2010-02-27 | 2015-11-17 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| US9687476B2 (en) | 2010-02-27 | 2017-06-27 | Bayer Intellectual Property Gmbh | Bisaryl-bonded aryltriazolones and use thereof |
| US8673903B2 (en) | 2010-05-14 | 2014-03-18 | Bayer Intellectual Property Gmbh | Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof |
| US9180120B2 (en) | 2010-09-02 | 2015-11-10 | Bayer Intellectual Property Gmbh | Substituted N-phenethyltriazoloneacetamides and use thereof |
| US9034855B2 (en) | 2010-09-16 | 2015-05-19 | Bayer Intellectual Property Gmbh | Substituted phenylacetate and phenylpropane amides and use thereof |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| US11752106B2 (en) | 2012-02-27 | 2023-09-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10272046B2 (en) | 2012-02-27 | 2019-04-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US11147770B2 (en) | 2012-02-27 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US10053428B2 (en) | 2012-07-20 | 2018-08-21 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| US9688636B2 (en) | 2012-07-20 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
| US8981104B2 (en) | 2012-07-20 | 2015-03-17 | Bayer Pharma Aktiengesellschaft | 5-aminotetrahydroquinoline-2-carboxylic acids and their use |
| US9714213B2 (en) | 2013-10-15 | 2017-07-25 | Toa Eiyo Ltd. | 4-aminomethylbenzoic acid derivative |
| RU2673245C2 (ru) * | 2013-10-15 | 2018-11-23 | Тоа Эйо Лтд. | Производные 4-аминометилбензойной кислоты |
| CN105658621A (zh) * | 2013-10-15 | 2016-06-08 | 东亚荣养株式会社 | 4-氨甲基苯甲酸衍生物 |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US9771352B2 (en) | 2014-11-03 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| US11166932B2 (en) | 2015-07-23 | 2021-11-09 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof |
| US10336749B2 (en) | 2015-08-21 | 2019-07-02 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
| USRE49826E1 (en) | 2015-08-21 | 2024-02-06 | Bayer Pharma Aktiengesellschaft | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
| US10759794B2 (en) | 2015-12-10 | 2020-09-01 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
| US10414765B2 (en) | 2015-12-10 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same |
| US11091463B2 (en) | 2016-05-03 | 2021-08-17 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| US10472348B2 (en) | 2016-05-03 | 2019-11-12 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| US10722501B2 (en) | 2016-05-09 | 2020-07-28 | Bayer Aktiengesellschaft | Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof |
| US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
| US11098063B2 (en) | 2017-06-14 | 2021-08-24 | Bayer Aktiengesellschaft | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders |
| US11173151B2 (en) | 2017-10-24 | 2021-11-16 | Bayer Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11331314B2 (en) | 2017-10-24 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Amine substituted triazole derivatives and uses thereof |
| US11298367B2 (en) | 2017-10-24 | 2022-04-12 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
| US11230540B2 (en) | 2017-10-24 | 2022-01-25 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002070510A2 (de) | 2002-09-12 |
| EP1368335A2 (de) | 2003-12-10 |
| CA2439756C (en) | 2011-01-11 |
| US20070179139A1 (en) | 2007-08-02 |
| JP2004529111A (ja) | 2004-09-24 |
| DE10110750A1 (de) | 2002-09-12 |
| AU2002234645A1 (en) | 2002-09-19 |
| WO2002070510A3 (de) | 2003-01-30 |
| US7705043B2 (en) | 2010-04-27 |
| CA2439756A1 (en) | 2002-09-12 |
| JP4535679B2 (ja) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7705043B2 (en) | Substituted aminodicarboxylic acid derivatives having pharmaceutical properties | |
| US20040176446A1 (en) | Substituted amino dicarboxylic acid derivatives | |
| RU2280025C9 (ru) | Новые производные аминодикарбоновых кислот, обладающие фармацевтическими свойствами | |
| US7329777B2 (en) | Methods for treating heart failure, thromboembolic disorders, and pulmonary fibrosis | |
| ZA200201138B (en) | Novel dicarboxylic acid derivatives with pharmaceutical properties. | |
| US6939989B2 (en) | Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BAYER AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALONSO-ALIJA, CRISTINA;HARTER, MICHAEL;HAHN, MICHAEL;AND OTHERS;REEL/FRAME:014204/0831;SIGNING DATES FROM 20030728 TO 20030812 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
| AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY Free format text: MERGER;ASSIGNOR:BAYER HEALTHCARE AG;REEL/FRAME:023769/0122 Effective date: 20081204 |